Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06377371 · ClinicalTrials.gov registry record · Phase 4
Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE
A Phase 4 study of Meningioma, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06377371 is a Phase 4 study of Meningioma that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 20 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06377371, a Phase 4 study of Meningioma, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Brain Imaging with [Cu64]DOTATATE
- PROCEDURE Radio-guided Surgery With Neoprobe Utilization
Study Locations (1)
New York
- New York-Presbyterian/Weill Cornell Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-09-11 |
| Est. Completion | 2027-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06377371
The ClinicalTrials.gov registry entry for NCT06377371 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (80% lower). The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 2 interventions - of which Brain Imaging with [Cu64]DOTATATE is the first listed.
NCT06377371 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06377371 about?
NCT06377371 is a clinical study titled "Feasibility of Intraoperative Tracing of Meningioma Using [Cu64]DOTATATE". The study team hypothesizes that it is feasible to intraoperatively detect tumor following \[CU64\]DOTATATE injection using the gamma probe device.
What is the current status of trial NCT06377371?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-09-11. Estimated completion is 2027-01.
What conditions does trial NCT06377371 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT06377371?
The interventions under investigation include: Brain Imaging with [Cu64]DOTATATE (DIAGNOSTIC_TEST), Radio-guided Surgery With Neoprobe Utilization (PROCEDURE).
Who is sponsoring clinical trial NCT06377371?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06377371 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors.
RECRUITING · Phase 4
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
-
Cabozantinib for Patients With Recurrent or Progressive Meningioma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.